Pfizer’s tofacitinib heads Rigel, Vertex, and Incyte as first oral RA candidate
This article was originally published in Scrip
Executive Summary
Pfizer's novel oral JAK inhibitor, tofacitinib (formerly tasocitinib; CP-690,550) has met the primary endpoints in a second Phase III trial in patients with active rheumatoid arthritis.